Percepta -- Bioscience questions answered.Percepta -- Bioscience questions answered.Percepta -- Bioscience questions answered.
bioscience. questions. answered.

In US and Canada Call Toll Free: (877) 597-9236
Everywhere Else Call: (760) 431-6300

Reports

2007 Gene Silencing Dashboard Series 1 -

pic_gene_silencingCatalog number: 0702GSL
Publication date: February 2007
Company-wide electronic copy: Complimentary

Please enquire about single-user* electronic copy pricing
* single-user pricing is intended for small companies, of 40 or less employees, to access The Life Science Dashboard. Please order these copies directly with Percepta Associates.

Overview

Overview

RNA interference is rapidly emerging as a integral tool to the study of the physiological role of gene products. RNAi-based methods allow researchers to modulate and in many cases dramatically reduce expression of a gene of interest. Systems for delivering RNAs into cells for the purpose of gene silencing include standard transfection technologies as well as plasmid and viral systems for the inducible expression of siRNAs in vivo.

The Gene Silencing Dashboard™ was developed from responses to a 36-question survey completed by 367 scientists predominantly located in North America and Europe. This Dashboard reveals key market indicators for the gene silencing market as a whole as well as for the following methods representing market sub-segments:

  • RNAi screens using siRNA libraries (sets of 50 or more siRNAs)
  • Inducing siRNAs in vivo from a plasmid or other vector in cells
  • Delivering synthetic siRNAs into cells
  • Digesting long dsRNA in vivo using dicer or other enzymes
  • Expressing siRNA in vitro for delivery into cells
  • Using PCR mediated siRNA expression cassettes to generate siRNAs
  • Delivering siRNAs into cells by transfection
  • Delivering siRNAs into cells by electroporation
  • Delivering siRNAs into cells by viral infection
  • Using a reporter systems to track gene knockdown

In order to dive more deeply into the characteristics and dynamics of the market for gene silencing products, Percepta has introduced the Gene Silencing Dashboard™, designed to take a snapshot of the current market landscape with the future goal of repeating and publishing the study to give Dashboard readers the ongoing story of how the market is adapting to new products, new competitors and new sales and marketing strategies.

Survey Methodology

In November/December of 2006, Percepta fielded three surveys to our panel of active life scientists:

  • Nucleic Acid Purification and Amplification Survey
  • Gene Silencing and Gene Expression Profiling Survey
  • Mammalian Transfection and Cell Culture Survey

This report reveals the results of the Gene Silencing section of the Gene Silencing and Gene Expression Profiling Survey. The results of the Gene Expression Profiling portion of the survey as well as the other two studies are available as separate Life Science Dashboard™ publications. Contact Percepta for more information on these additional reports.

Individuals were invited by e-mail blast to click through to a webpage at bioanalytix.com where the survey was hosted. Invitations were delivered on November 13, 2006 and results collected through December 8. A total of 367 scientists completed the survey, of which 162 are actively engaged in performing RNAi/siRNA experiments.

Respondent Demographics

Respondents from the academic, government and commercial market segments are well represented, with approximately 18% of respondents employed in an industry setting. About 78% of respondents are from North America, while 18% reside in Europe.

Junior (Lab Tech, Grad Students), mid level (Post-Doc, Lab Manager) and senior (Professor/PI, Group Leader) scientists are well represented in the data set, with the most cited job titles being Scientist/Senior Scientist (21.3% of respondents) and Post-Doctoral Fellow (19.1%).

A wide variety of scientific areas of specialization is also evident, led by cell biology (named by 17.3% of respondents as their primary area of expertise) and biochemistry (named by 16.2% of respondents). Immunology (8.5%), microbiology/ infectious disease/ virology (7.9%) and genomics (7.9%) are the only other applications named by more than 5% of respondents.

Small (1-5 scientists), medium (6-20 scientists) and large (>20 scientists) laboratories are well represented: 32.3% of respondents work in labs where 1 to 5 people perform experiments; 52.7% in labs with 6 to 20 experimenters, and the remaining 15.0% in labs with greater than 20 bench scientists.

Table of contents

Table of Contents

  • Figures and Tables
  • Executive Summary
  • Key Findings and Implications
  • Gene Silencing Dashboard
  • Gene Silencing Market Opportunity Matrix
  • Survey Methodology
  • Survey Invitation Text
  • Respondent Demographics
  • Frequency of Performance of Molecular Biology Techniques
  • Frequency of Performance of Gene Silencing Techniques
  • Reaction Throughput and Market Growth Rates
  • Respondent’s Stated Price Per Reaction
  • Total Market Size, Market Segment Sizes and Total Market Growth Rate
  • Market Shares by Segment (Share of Mention)
  • Customer Satisfaction And Interest In Switching Suppliers
  • Product Features That Influence Purchasing Decisions
  • Primary Downstream Applications
  • Desired Changes to Gene Silencing Products
  • Survey Questionnaire

Figures and Tables

  • Figure 1: Respondent’s Place of Employment
  • Figure 2: Respondent’s Country/Region
  • Figure 3: Respondent’s Job Title
  • Figure 4: Respondent’s Areas of Expertise/Specialization
  • Figure 5: Number of Employees in Respondent’s Laboratories
  • Figure 6: Percentage of Respondents Performing Various Techniques at Least a Few Times per Year
  • Figure 7: Percentage of Respondents Performing RNAi/siRNA Experiments
  • Figure 8: Percentage of Respondents Performing Various Gene Silencing Techniques at Least a Few Times per Year
  • Figure 9: Percentage of Respondents That Perform RNAi Screens Using siRNA Libraries
  • Figure 10: Percentage of Respondents That Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
  • Figure 11: Percentage of Respondents That Deliver Synthetic siRNAs into Cells
  • Figure 12: Percentage of Respondents That Digest Long dsRNA in vivo using Dicer or Other Enzymes
  • Figure 13: Percentage of Respondents That Express siRNA in vitro for Delivery into Cells
  • Figure 14: Percentage of Respondents That Use PCR Mediated siRNA Expression Cassettes to Generate siRNAs
  • Figure 15: Percentage of Respondents That Deliver siRNAs into Cells by Transfection
  • Figure 16: Percentage of Respondents That Deliver siRNAs into Cells by Electroporation
  • Figure 17: Percentage of Respondents That Deliver siRNAs into Cells by Viral Infection
  • Figure 18: Percentage of Respondents That Use a Reporter Systems to Track Gene Knockdown
  • Figure 19: Respondent’s Primary Supplier for RNAi Screens Using siRNA Libraries
  • Figure 20: Respondent’s Primary Supplier for Products to Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
  • Figure 21: Respondent’s Primary Supplier for Products to Deliver Synthetic siRNAs into Cells
  • Figure 22: Respondent’s Primary Supplier for Products to Digest Long dsRNA in vivo using Dicer or Other Enzymes
  • Figure 23: Respondent’s Primary Supplier for Products to Express siRNA in vitro for Delivery into Cells
  • Figure 24: Respondent’s Primary Supplier for PCR Mediated siRNA Expression Cassettes to Generate siRNAs
  • Figure 25: Respondent’s Primary Supplier for Products to Deliver siRNAs into Cells by Transfection
  • Figure 26: Respondent’s Primary Supplier for Products to Deliver siRNAs into Cells by Electroporation
  • Figure 27: Respondent’s Primary Supplier for Products to Deliver siRNAs into Cells by Viral Infection
  • Figure 28: Respondent’s Primary Supplier of Reporter Systems to Track Gene Knockdown
  • Figure 29: Percentage of Respondents That Have Switched Suppliers in the Last Six Months
  • Figure 30: Most Important Features of Products for Gene Silencing Experiments
  • Figure 31: Respondent’s Primary Downstream Application for RNAi Screens Using siRNA Libraries
  • Figure 32: Respondent’s Primary Downstream Application for Products to Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
  • Figure 33: Respondent’s Primary Downstream Application for Products to Deliver Synthetic siRNAs into Cells
  • Figure 34: Respondent’s Primary Downstream Application for Products to Digest Long dsRNA in vivo using Dicer or Other Enzymes
  • Figure 35: Respondent’s Primary Downstream Application for Products to Express siRNA in vitro for Delivery into Cells
  • Figure 36: Respondent’s Primary Downstream Application for PCR Mediated siRNA Expression Cassettes to Generate siRNAs
  • Figure 37: Respondent’s Primary Downstream Application for Products to Deliver siRNAs into Cells by Transfection
  • Figure 38: Respondent’s Primary Downstream Application for Products to Deliver siRNAs into Cells by Electroporation
  • Figure 39: Respondent’s Primary Downstream Application for Products to Deliver siRNAs into Cells by Viral Infection
  • Figure 40: Respondent’s Primary Downstream Application for Reporter Systems to Track Gene Knockdown
  • Table 1: Frequency of Performance of Various Techniques
  • Table 2: Frequency of Co-Performance of Various Molecular Biology Techniques
  • Table 3: Frequency of Performance of Gene Silencing Methods
  • Table 4: Frequency of Co-Performance of Life Science Techniques with Gene Silencing Methods
  • Table 5: Frequency of Co-Performance of Gene Silencing Methods with Life Science Techniques
  • Table 6: Median and Average Monthly Throughput for Gene Silencing Products
  • Table 7: Percentage of Respondents Performing Various Numbers of Gene Silencing Reactions Per Month
  • Table 8: Projected Growth in the Performance of Various Gene Silencing Techniques
  • Table 9: Median and Average Price Per Prep for Gene Silencing Products
  • Table 10: Market Share Leaders for Gene Silencing Products
  • Table 11: Percentage of Respondents Satisfied with Various Gene Silencing Products and Reasons for Dissatisfaction
  • Table 12: Respondents Primary Application After Various Gene Silencing Methods

Copyright © 2017 Percepta Associates Inc. All rights reserved. Terms & Conditions.Designed by Audacity